Results 51 to 60 of about 75,041 (254)

Glucagon-like peptide-1 agonist use for obesity treatment in patients with left ventricular assist devices

JHLT Open
Glucagon-like peptide-1 agonists are effective weight loss treatments, yet few data are available regarding their use in patients with durable left ventricular assist devices.
Michele Edwards, MSN, APRN, Melanie Thomas, MSN, APRN, Maryjane Farr, MD, MSc, Densey Varghese, MSN, APRN, Lauren K. Truby, MD, MS, Jennifer T. Thibodeau, MD, MSCS, Mark H. Drazner, MD, MSc, Matthias Peltz, MD, Justin L. Grodin, MD, MPH, Nicholas S. Hendren, MD   +9 more
doaj   +1 more source

Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases [PDF]

Frontiers in Neuroscience, 2019
Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis of brain impairment caused by chronic hyperglycemia is complex and includes mitochondrial dysfunction, neuroinflammation, neurotransmitters' alteration, and vascular disease, which lead to cognitive impairment, neurodegeneration, loss of synaptic plasticity ...
Grieco M., Giorgi A., Gentile M. C., d'Erme M., Morano S., Maras B., Filardi T.   +6 more
openaire   +4 more sources

Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics

Nature Communications, 2020
Glucagon-like peptide-1 receptor is an important regulator of appetite and glucose homeostasis. Here the authors describe super-resolution microscopy and in vivo imaging compatible fluorescent probes, which reveal endogenous glucagon-like peptide-1 ...
Julia Ast, Anastasia Arvaniti, Nicholas H. F. Fine, Daniela Nasteska, Fiona B. Ashford, Zania Stamataki, Zsombor Koszegi, Andrea Bacon, Ben J. Jones, Maria A. Lucey, Shugo Sasaki, Daniel I. Brierley, Benoit Hastoy, Alejandra Tomas, Giuseppe D’Agostino, Frank Reimann, Francis C. Lynn, Christopher A. Reissaus, Amelia K. Linnemann, Elisa D’Este, Davide Calebiro, Stefan Trapp, Kai Johnsson, Tom Podewin, Johannes Broichhagen, David J. Hodson   +25 more
doaj   +1 more source

Direct visualization of glucagon‐like peptide‐1 secretion by fluorescent fusion proteins

Journal of Diabetes Investigation, 2022
Live‐cell imaging with fluorescent proteins (FPs) is a powerful tool for investigating the exocytosis processes of hormones. However, the secretion process of glucagon‐like peptide‐1 (GLP‐1) has not been visualized by FPs, which might be because tagging ...
Atsushi Tsuzuki, Yoichiro Fujioka, Aiko Yoshida, Sayaka Kashiwagi, Maho Amano, Tohru Hira, Akinobu Nakamura, Hideaki Miyoshi, Tatsuya Atsumi, Yusuke Ohba   +9 more
doaj   +1 more source

Glucagon‐like peptide 1: A potent glycogenic hormone [PDF]

FEBS Letters, 1994
GLP‐1(7–36)amide is an insulinotropic peptide derived from the intestinal post‐translational proglucagon process, the release of which is increased mainly after a carbohydrate meal; also, its anti‐diabetogenic effect in normal and diabetic states has been reported.
Valverde, Isabel, Morales, Mónica, Clemente, Felipe, López-Delgado, Maria I., Delgado, Elena, Perea, Almudena, Villanueva-Peñacarrillo, Maria L.   +6 more
openaire   +2 more sources

Glucagon‐Like Peptide‐1 Receptor Agonist Use in Obese Patients Is Associated With Decreased Risk of Revision and Retears After Arthroscopic Rotator Cuff Repair

Arthroscopy, EarlyView.
Purpose To evaluate the impact of preoperative glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) use on medical complications, emergency department use, and orthopaedic complications in obese patients undergoing arthroscopic rotator cuff repair. Methods Obese patients (defined by relevant ICD‐10 codes and confirmed by body mass index measurements ...
Argen Omurzakov, Arsen M. Omurzakov, Robert J. Burkhart, James E. Voos, Jacob G. Calcei, John M. Apostolakos   +5 more
wiley   +1 more source

The deletion of glucagon-like peptide-1 receptors expressing neurons in the dorsomedial hypothalamic nucleus disrupts the diurnal feeding pattern and induces hyperphagia and obesity

Nutrition & Metabolism, 2021
Background Feeding rhythm disruption contributes to the development of obesity. The receptors of glucagon-like peptide-1 (GLP-1) are distributed in the wide regions of the brain.
Yuko Maejima, Shoko Yokota, Masaru Shimizu, Shoichiro Horita, Daisuke Kobayashi, Akihiro Hazama, Kenju Shimomura   +6 more
doaj   +1 more source

Cardiovascular Effects of Glucagon-Like Peptide 1

Mini-Reviews in Medicinal Chemistry, 2011
Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance.
Papazafiropoulou, A., Pappas, S. I., Papadogiannis, D., Tentolouris, N.   +3 more
openaire   +3 more sources

Gut Health in Ostriches (Struthio camelus): Insights Into Intestinal Structure, Functions, Microbiome, and Improvement Strategies

Animal Research and One Health, EarlyView.
Our paper systematically reviews the intestinal structure, function, and microbiota of ostriches, along with strategies for improving their gut health. We analyze how these factors collectively influence intestinal homeostasis and ostrich welfare, emphasizing probiotics as a promising intervention to enhance gut health, boost population well‐being, and
Zi‐Qun Zhang, Fang‐Fang Guo, Wen‐Juan Du, Meng Li, Aftab Shaukat, Zhu‐Qing Jia, Shu‐Cheng Huang   +6 more
wiley   +1 more source

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner

Communications Biology, 2021
Li, Chen, Vong, Zhao et al. show that glucagon-like peptide-1 receptor agonist reverses transcriptomic aging signatures in mouse glial and neurovascular cells.
Zhongqi Li, Xinyi Chen, Joaquim S. L. Vong, Lei Zhao, Junzhe Huang, Leo Y. C. Yan, Bonaventure Ip, Yun Kwok Wing, Hei-Ming Lai, Vincent C. T. Mok, Ho Ko   +10 more
doaj   +1 more source